MicuRx MRX-5 Gets FDA Nod for Phase II NTM Lung Disease Study
MicuRx Pharmaceuticals Inc., (SHA: 688373) a Sino‑US biopharmaceutical company, announced it has received approval from...
Huiyu Pharma HYP-6589 Gets NMPA Nod for NSCLC Osimertinib Combo
Sichuan Huiyu Pharmaceutical Co., Ltd. (SHA: 688553) announced that the National Medical Products Administration (NMPA)...
Servier Oncology Revenue Drives 16% Growth, US Sales Surge 70%
Servier announced a 16.2% year‑on‑year (YOY) revenue increase to EUR 6.9 billion (USD 7.52 billion) for the 2024/25 financial...
Changchun High‑Tech’s Firsekibart Filing Accepted for Non‑Infectious Uveitis
Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that the National Medical Products...
Danaher Q4 Revenue Grows 3% to $24.6B on Biotech and Diagnostics Innovation
Danaher Corporation (NYSE: DHR) reported fourth‑quarter and full‑year 2025 earnings with global revenues rising 3% year‑on‑year...
Distinct Healthcare IPO Hong Kong: Private Provider Seeks $36M HKEX Listing
Distinct Healthcare Holdings Limited, a China‑based private healthcare service provider, released its prospectus this week...
Merck Establishes Chongqing China Branch in Milestone Expansion
Merck Sharp & Dohme (MSD, NYSE: MRK), a US‑based biopharmaceutical giant, announced the establishment of a...
Biogen’s Litifilimab Secures FDA Breakthrough Therapy Designation for Lupus
Biogen Inc. (NASDAQ: BIIB) announced that its investigational litifilimab has received Breakthrough Therapy Designation (BTD) from...
Seamless Therapeutics Partners with Eli Lilly on $1.12B Hearing Loss Recombinase Deal
Seamless Therapeutics, a Germany‑based gene editing company, announced a global strategic research collaboration and license...
Sino Biopharm’s TQA3605 Meets Endpoint in Hepatitis B Phase II Trial
Sino Biopharmaceutical Ltd (HKG: 1177) announced that its Category 1 drug TQA3605 has met the primary...
J&J Darzalex Faspro Gets FDA Nod for NDMM D-VRd Regimen
Johnson & Johnson (J&J, NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA) approved...
Roche CT-388 Obesity Drug Shows 22.5% Weight Loss in Phase II Trial
Roche (SWX: ROG, OTCMKTS: RHHBY) announced positive topline results from its Phase II clinical trial (CT388‑103)...
FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link
The U.S. Food and Drug Administration this month requested that Novo Nordisk and Eli Lilly...
Leqvio Gets NMPA Nod for Monotherapy in China Hypercholesterolemia
Novartis (NYSE: NVS) announced that Leqvio (inclisiran) has received an additional indication approval from the National...
Apeloa Partners with MindRank on AI Drug Development Platform
Apeloa Pharmaceutical Co., Ltd. (SHE: 000739), a China‑based contract development and manufacturing organization (CDMO), announced...
China Drug Administration Implementation Regulations Set for May 2026 Launch
China’s State Council this week issued the Implementation Regulations of the Drug Administration Law, a...
Henlius Triple Combo Gets NMPA Nod for Advanced Solid Tumor Trials
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced it has received National Medical Products Administration (NMPA)...
Hengrui’s HRS-5346 Lp(a) Inhibitor Gets China Breakthrough Therapy Designation in $1.97B Merck Deal
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS-5346, the centerpiece of a USD 1.97 billion...
IVD Medical Launches Nipah Virus Detection Kit with AI Early Warning Platform
IVD Medical Holding Ltd (HKG: 1931), a China‑based in vitro diagnostic specialist, announced the launch...
Betta Pharmaceuticals’ BPI-572270 RAS Inhibitor Gets NMPA Nod for Solid Tumor Trials
Betta Pharmaceuticals (SHE: 300558) announced that the National Medical Products Administration (NMPA) has approved the...